| Name | udp glucuronosyltransferase 2B7 |
|---|---|
| Synonyms | UDP glucuronosyltransferase 2B7; UDPGT; UDP glucuronosyltransferase 2B7 precursor; UDPGTh 2; UGT2B7; UGT2B7 protein; UGT2B9; UGTB2B9… |
| Name | 1-naphthol |
|---|---|
| CAS | 1-naphthalenol |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18647858 | Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, Miners JO: Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol. 2008 Oct;74(4):1152-62. Epub 2008 Jul 22. |
85(1,1,1,5) | Details |
| 20145913 | Donato MT, Montero S, Castell JV, Gomez-Lechon MJ, Lahoz A: Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Anal Bioanal Chem. 2010 Mar;396(6):2251-63. Epub 2010 Feb 10. The assays are based on analysis and quantification by high-performance liquid chromatography-tandem mass spectrometry of glucuronides formed from selective probe substrates, namely, (UGT1A1, 3- 1-naphthol (UGT1A6), propofol (UGT1A9), and naloxone (UGT2B7). |
32(0,1,1,2) | Details |
| 9364930 | Belanger G, Beaulieu M, Levesque E, Hum DW, Belanger A: Expression and characterization of a novel UDP-glucuronosyltransferase, UGT2B9, from cynomolgus monkey. DNA Cell Biol. 1997 Oct;16(10):1195-205. The activity of UGT2B9 was tested with over 60 compounds and was demonstrated to be active on C18, C19, and C21 steroids, bile acids, and several xenobiotics including 1-naphthol, and |
10(0,0,1,5) | Details |
| 15788539 | Di Marco A, D'Antoni M, Attaccalite S, Carotenuto P, Laufer R: Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos. 2005 Jun;33(6):812-9. Epub 2005 Mar 23. The major UGT isoforms identified were UGT1A6, UGT1A7, and UGT1A9 for 4-methylumbelliferone; UGT1A6 and UGT1A8 for 1-naphthol; UGT2B7 for naloxone; UGT1A3 and UGT2B7 for ketoprofen; and UGT1A4 for trifluoperazine. |
6(0,0,1,1) | Details |
| 19487247 | Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO: Influence of N-terminal domain and residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos. 2009 Sep;37(9):1948-55. Epub 2009 Jun 1. The conserved N-terminal domain of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to and 34 of UGT2B10 was substituted with and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and was characterized. |
2(0,0,0,2) | Details |
| 10901286 | Sabolovic N, Magdalou J, Netter P, Abid A: Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7. Life Sci. 2000;67(2):185-96. Glucuronidation of phenols (1-naphthol, 4-methylumbelliferone) and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ketoprofen, and carprofen was investigated in human colon carcinoma Caco-2 cell clones. RT-PCR experiments indicated that the PD-7 and TC-7 clones expressed the UDP-glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A3 and UGT2B7, which could account for the glucuronidation of phenols and carboxylic acids observed. |
2(0,0,0,2) | Details |
| 17301691 | Kurkela M, Patana AS, Mackenzie PI, Court MH, Tate CG, Hirvonen J, Goldman A, Finel M: Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenet Genomics. 2007 Feb;17(2):115-26. Using 1-naphthol as the aglycone substrate, the Km of 6YD for the cosubstrate UDP- was about 50 times higher than in UGT1A6. Coexpression also influenced wild-type UGT1A6 and UGT2B7, increasing the normalized activity of UGT1A6, but decreasing it for UGT2B7. |
1(0,0,0,1) | Details |